Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

Corrigendum: Suppression of vascular permeability and inflammation by targeting of the transcription factor c-Jun.

Fahmy RG, Waldman A, Zhang G, Mitchell A, Tedla N, Cai H, Geczy CR, Chesterman CN, Perry M, Khachigian LM.

Nat Biotechnol. 2015 Aug;33(8):882. doi: 10.1038/nbt0815-882c. No abstract available.

PMID:
26252146
2.

Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER).

Cho EA, Moloney FJ, Cai H, Au-Yeung A, China C, Scolyer RA, Yosufi B, Raftery MJ, Deng JZ, Morton SW, Hammond PT, Arkenau HT, Damian DL, Francis DJ, Chesterman CN, Barnetson RS, Halliday GM, Khachigian LM.

Lancet. 2013 May 25;381(9880):1835-43. doi: 10.1016/S0140-6736(12)62166-7. Epub 2013 May 7.

3.

DNAzyme targeting c-jun suppresses skin cancer growth.

Cai H, Santiago FS, Prado-Lourenco L, Wang B, Patrikakis M, Davenport MP, Maghzal GJ, Stocker R, Parish CR, Chong BH, Lieschke GJ, Wong TW, Chesterman CN, Francis DJ, Moloney FJ, Barnetson RS, Halliday GM, Khachigian LM.

Sci Transl Med. 2012 Jun 20;4(139):139ra82. doi: 10.1126/scitranslmed.3003960.

4.

c-Jun DNAzymes inhibit myocardial inflammation, ROS generation, infarct size, and improve cardiac function after ischemia-reperfusion injury.

Luo X, Cai H, Ni J, Bhindi R, Lowe HC, Chesterman CN, Khachigian LM.

Arterioscler Thromb Vasc Biol. 2009 Nov;29(11):1836-42. doi: 10.1161/ATVBAHA.109.189753. Epub 2009 Jul 10.

PMID:
19592465
5.

Modulation of platelet and leucocyte function by a Chinese herbal formulation as compared with conventional antiplatelet agents.

Zhao L, Gaudry L, Dunkley S, Brighton T, Guo ZX, Ye ZL, Luo RZ, Chesterman CN.

Platelets. 2008 Feb;19(1):24-31. doi: 10.1080/09537100701286123.

PMID:
18231935
6.

Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies.

Bhindi R, Fahmy RG, Lowe HC, Chesterman CN, Dass CR, Cairns MJ, Saravolac EG, Sun LQ, Khachigian LM.

Am J Pathol. 2007 Oct;171(4):1079-88. Epub 2007 Aug 23. Review.

7.

Yin Yang-1 inhibits vascular smooth muscle cell growth and intimal thickening by repressing p21WAF1/Cip1 transcription and p21WAF1/Cip1-Cdk4-cyclin D1 assembly.

Santiago FS, Ishii H, Shafi S, Khurana R, Kanellakis P, Bhindi R, Ramirez MJ, Bobik A, Martin JF, Chesterman CN, Zachary IC, Khachigian LM.

Circ Res. 2007 Jul 20;101(2):146-55. Epub 2007 Jun 7.

PMID:
17556661
8.

Hypothesis for control of von Willebrand factor multimer size by intra-molecular thiol-disulphide exchange.

Ganderton T, Berndt MC, Chesterman CN, Hogg PJ.

J Thromb Haemost. 2007 Jan;5(1):204-6. Epub 2006 Oct 24. No abstract available.

9.

Suppression of vascular permeability and inflammation by targeting of the transcription factor c-Jun.

Fahmy RG, Waldman A, Zhang G, Mitchell A, Tedla N, Cai H, Geczy CR, Chesterman CN, Perry M, Khachigian LM.

Nat Biotechnol. 2006 Jul;24(7):856-63. Epub 2006 Jul 2. Erratum in: Nat Biotechnol. 2015 Aug;33(8):882. Nat Biotechnol. 2015 Aug;33(8):882.

PMID:
16823369
10.

Blood level of phosphoglycerate kinase does not correlate with presence or extent of tumor.

Daly EB, Chen G, Sun L, Friedlander M, Goldstein D, Beer DG, Chesterman CN, Hogg PJ.

Int J Biol Markers. 2004 Apr-Jun;19(2):170-2. No abstract available.

PMID:
15255553
11.

Role of thrombospondin-1 in control of von Willebrand factor multimer size in mice.

Pimanda JE, Ganderton T, Maekawa A, Yap CL, Lawler J, Kershaw G, Chesterman CN, Hogg PJ.

J Biol Chem. 2004 May 14;279(20):21439-48. Epub 2004 Feb 23.

12.

Congenital thrombotic thrombocytopenic purpura in association with a mutation in the second CUB domain of ADAMTS13.

Pimanda JE, Maekawa A, Wind T, Paxton J, Chesterman CN, Hogg PJ.

Blood. 2004 Jan 15;103(2):627-9. Epub 2003 Sep 25.

13.

Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth.

Fahmy RG, Dass CR, Sun LQ, Chesterman CN, Khachigian LM.

Nat Med. 2003 Aug;9(8):1026-32. Epub 2003 Jul 20.

PMID:
12872165
14.

Novel and emerging therapies in cardiology and haematology.

Pimanda JE, Lowe HC, Hogg PJ, Chesterman CN, Khachigian LM.

Curr Drug Targets Cardiovasc Haematol Disord. 2003 Jun;3(2):101-23. Review.

PMID:
12769638
15.

Blockade of vascular smooth muscle cell proliferation and intimal thickening after balloon injury by the sulfated oligosaccharide PI-88: phosphomannopentaose sulfate directly binds FGF-2, blocks cellular signaling, and inhibits proliferation.

Francis DJ, Parish CR, McGarry M, Santiago FS, Lowe HC, Brown KJ, Bingley JA, Hayward IP, Cowden WB, Campbell JH, Campbell GR, Chesterman CN, Khachigian LM.

Circ Res. 2003 May 2;92(8):e70-7. Epub 2003 Apr 10.

PMID:
12690039
16.

A perspective on the measurement of ADAMTS13 in thrombotic thrombocytopaenic purpura.

Pimanda JE, Chesterman CN, Hogg PJ.

Eur J Haematol. 2003 Apr;70(4):257-62. Review.

PMID:
12656756
17.
18.

Overstretch stent injury to the rat aorta leads to in-stent restenosis.

Lowe HC, Oesterle SN, MacNeill BD, James B, Chesterman CN, Khachigian LM.

Am J Cardiol. 2002 Apr 15;89(8):1010. No abstract available.

PMID:
11950452
19.
20.

Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study.

Chong BH, Gallus AS, Cade JF, Magnani H, Manoharan A, Oldmeadow M, Arthur C, Rickard K, Gallo J, Lloyd J, Seshadri P, Chesterman CN; Australian HIT Study Group.

Thromb Haemost. 2001 Nov;86(5):1170-5.

PMID:
11816702
21.

Catalytic oligodeoxynucleotides define a key regulatory role for early growth response factor-1 in the porcine model of coronary in-stent restenosis.

Lowe HC, Fahmy RG, Kavurma MM, Baker A, Chesterman CN, Khachigian LM.

Circ Res. 2001 Oct 12;89(8):670-7.

PMID:
11597989
22.

Coronary stent thrombosis: insights from the porcine coronary stent model.

Lowe HC, Kumar RK, Chesterman CN, Fahmy RG, Khachigian LM.

Thromb Haemost. 2001 Sep;86(3):937-8. No abstract available.

PMID:
11583335
23.

Rat aortic stenting: toward a simple model of in-stent restenosis.

Lowe HC, Chesterman CN, Khachigian LM.

Am J Cardiol. 2001 Sep 15;88(6):720-1. No abstract available.

PMID:
11569492
24.

Does thrombus contribute to in-stent restenosis in the porcine coronary stent model?

Lowe HC, Chesterman CN, Khachigian LM.

Thromb Haemost. 2001 Jun;85(6):1117-8. No abstract available.

PMID:
11434694
25.

Control of von Willebrand factor multimer size by thrombospondin-1.

Xie L, Chesterman CN, Hogg PJ.

J Exp Med. 2001 Jun 18;193(12):1341-9.

26.

Platelet-derived growth factor enhances granulopoiesis via bone marrow stromal cells.

Yang M, Li K, Lam AC, Yuen PM, Fok TF, Chesterman CN, Chong BH.

Int J Hematol. 2001 Apr;73(3):327-34.

PMID:
11345198
27.

Lupus antibody bivalency is required to enhance prothrombin binding to phospholipid.

Field SL, Chesterman CN, Dai YP, Hogg PJ.

J Immunol. 2001 May 15;166(10):6118-25.

28.

Acute local release of fibroblast growth factor-2 but not transforming growth factor-beta1 following coronary stenting.

Lowe HC, Chesterman CN, Hopkins AP, Juergens CP, Khachigian LM.

Thromb Haemost. 2001 Mar;85(3):574-6. No abstract available.

PMID:
11307842
29.

Early growth response factor-1 mediates insulin-inducible vascular endothelial cell proliferation and regrowth after injury.

Gousseva N, Kugathasan K, Chesterman CN, Khachigian LM.

J Cell Biochem. 2001;81(3):523-34.

PMID:
11255235
30.

The clinical significance of antiphospholipid antibodies in patients without autoimmune disease.

Brighton TA, Chesterman CN.

Aust N Z J Med. 2000 Dec;30(6):693-703. Review. No abstract available.

PMID:
11198577
32.

Dependence on prothrombin for inhibition of activated protein C activity by lupus antibodies.

Field SL, Chesterman CN, Hogg PJ.

Thromb Haemost. 2000 Dec;84(6):1132-3. No abstract available.

PMID:
11154135
33.

Reduction of von Willebrand factor by endothelial cells.

Xie L, Chesterman CN, Hogg PJ.

Thromb Haemost. 2000 Sep;84(3):506-13.

PMID:
11019979
34.

Recent insights into antiphospholipid antibody-mediated thrombosis.

Field SL, Brighton TA, McNeil HP, Chesterman CN.

Baillieres Best Pract Res Clin Haematol. 1999 Sep;12(3):407-22. Review.

PMID:
10856978
35.

A novel approach to the assessment of variations in the human platelet count.

Buckley MF, James JW, Brown DE, Whyte GS, Dean MG, Chesterman CN, Donald JA.

Thromb Haemost. 2000 Mar;83(3):480-4.

PMID:
10744157
36.

Physical proximity and functional association of glycoprotein 1balpha and protein-disulfide isomerase on the platelet plasma membrane.

Burgess JK, Hotchkiss KA, Suter C, Dudman NP, Szöllösi J, Chesterman CN, Chong BH, Hogg PJ.

J Biol Chem. 2000 Mar 31;275(13):9758-66.

37.

Intracoronary blood sampling using the multifunction probing catheter does not cause platelet activation.

Lowe HC, Murray B, Chong BH, Chesterman CN, Khachigian LM.

J Invasive Cardiol. 2000 Mar;12(3):144-6.

PMID:
10731282
38.

New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury.

Santiago FS, Lowe HC, Kavurma MM, Chesterman CN, Baker A, Atkins DG, Khachigian LM.

Nat Med. 1999 Dec;5(12):1438. No abstract available.

PMID:
10581092
39.

Lupus anticoagulants form immune complexes with prothrombin and phospholipid that can augment thrombin production in flow.

Field SL, Hogg PJ, Daly EB, Dai YP, Murray B, Owens D, Chesterman CN.

Blood. 1999 Nov 15;94(10):3421-31.

40.

New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury.

Santiago FS, Lowe HC, Kavurma MM, Chesterman CN, Baker A, Atkins DG, Khachigian LM.

Nat Med. 1999 Nov;5(11):1264-9. Erratum in: Nat Med 1999 Dec;5(12):1438.

PMID:
10545992
41.

Characterization of the soluble form of the low density lipoprotein receptor-related protein (LRP).

Quinn KA, Pye VJ, Dai YP, Chesterman CN, Owensby DA.

Exp Cell Res. 1999 Sep 15;251(2):433-41.

PMID:
10471328
43.

Left main coronary artery stenosis after percutaneous transluminal coronary angioplasty: importance of remaining "minimally invasive".

Lowe HC, Chesterman CN, Khachigian LM.

Catheter Cardiovasc Interv. 1999 Feb;46(2):254-5. No abstract available.

PMID:
10348555
44.

Evolutionary conservation of circulating soluble low density lipoprotein receptor-related protein-like ("LRP-like") molecules.

Grimsley PG, Quinn KA, Chesterman CN, Owensby DA.

Thromb Res. 1999 May 1;94(3):153-64.

PMID:
10326762
45.

Microheterogeneity of beta-2 glycoprotein I: implications for binding to anionic phospholipids.

Brighton TA, Dai YP, Hogg PJ, Chesterman CN.

Biochem J. 1999 May 15;340 ( Pt 1):59-67.

46.

Early growth response factor-1 induction by injury is triggered by release and paracrine activation by fibroblast growth factor-2.

Santiago FS, Lowe HC, Day FL, Chesterman CN, Khachigian LM.

Am J Pathol. 1999 Mar;154(3):937-44.

47.

Quinine-dependent antibodies bind a restricted set of epitopes on the glycoprotein Ib-IX complex: characterization of the epitopes.

Burgess JK, Lopez JA, Berndt MC, Dawes I, Chesterman CN, Chong BH.

Blood. 1998 Oct 1;92(7):2366-73.

48.

Low density lipoprotein receptor-related protein (LRP) expression varies among Hep G2 cell lines.

Grimsley PG, Quinn KA, Chesterman CN, Owensby DA.

Thromb Res. 1997 Dec 15;88(6):485-98.

PMID:
9610960
49.

The effects of alcohol on coagulation and fibrinolytic factors: a controlled trial.

Dimmitt SB, Rakic V, Puddey IB, Baker R, Oostryck R, Adams MJ, Chesterman CN, Burke V, Beilin LJ.

Blood Coagul Fibrinolysis. 1998 Jan;9(1):39-45.

PMID:
9607117
50.

Heparin in the home: risks and benefits.

Chesterman CN.

Med J Aust. 1998 Mar 16;168(6):261-2. No abstract available.

PMID:
9549530

Supplemental Content

Loading ...
Support Center